- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02103179
VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC) (VEGF ECC)
March 31, 2014 updated by: Ming Kuang,MD,PhD, First Affiliated Hospital, Sun Yat-Sen University
VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway
The investigators study the VEGF signaling in ECC cell lines,patients and its mechanism in ECC growth, proliferation and apoptosis.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Several studies have documented the elevated expression of VEGF, VEGFR1 and VEGFR2 in cancer cell lines.
Another study observed a sequential elevation of VEGF in low-grade dysplasia, high-grade dysplasia and early stage liver cancer.
Clinical analyses have discovered the high expression of VEGF is correlated with tumor progression, vascular invasion, distal metastasis and poor prognosis.
However, few studies have been conducted to investigate the VEGF signaling in ECC cells and its possible mechanism in regulating ECC growth.Therefore,we try to clarify the mechanism of VEGF signal in ECC growth,proliferation and apoptosis.
Study Type
Observational
Enrollment (Anticipated)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- First Affiliated Hospital, Sun Yat-Sen University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 80 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Extrahepatic cholangiocarcinoma patients underwent surgical therapy
Description
Inclusion Criteria:
- Extrahepatic cholangiocarcinoma patients diagnosed through biopsy; two or more dynamic imagine with a diagnosis of Extrahepatic cholangiocarcinoma
- Child-Pugh A or B
- well preserved renal and hematopoietic Function
- receive surgical therapy
- achieve complete section accessed by contrast-enhanced CT
Exclusion Criteria:
- incomplete section
- remote metastasis
- Child-Pugh C
- combination with other hepatobiliary disease
- suffer from other tumors concurrently or in last five years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
ECC patients
Extrahepatic cholangiocarcinoma patients treated by surgical treatment
|
all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis.
Time Frame: the day when conducting surgery (day 1)
|
the sections would be collected as previously described.Western blot,immunohistochemistry,PCR would be conducted to find out the variation between the normal liver tissue and tumor,tumor and meta(if have).
|
the day when conducting surgery (day 1)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Ming Kuang, MD, First Affiliated Hospital, Sun Yat-Sen University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2006
Primary Completion (Anticipated)
April 1, 2014
Study Completion (Anticipated)
September 1, 2014
Study Registration Dates
First Submitted
March 31, 2014
First Submitted That Met QC Criteria
March 31, 2014
First Posted (Estimate)
April 3, 2014
Study Record Updates
Last Update Posted (Estimate)
April 3, 2014
Last Update Submitted That Met QC Criteria
March 31, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- k0113011-2013ECC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Extrahepatic Cholangiocarcinoma
-
Samsung Medical CenterUnknownBiliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) CancerKorea, Republic of
-
Fudan UniversityUnknownMalignant Neoplasm Other Gallbladder/Extrahepatic Bile DuctChina
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnUnresectable Extrahepatic Bile Duct Carcinoma | Recurrent Cholangiocarcinoma | Non-Resectable Cholangiocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IIIA Hilar Cholangiocarcinoma | Stage IIIB Hilar Cholangiocarcinoma | Stage IVA Hilar Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma and other conditionsUnited States
-
RedHill Biopharma LimitedCompletedCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, IntrahepaticUnited States
-
RedHill Biopharma LimitedAvailableCholangiocarcinoma | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Perihilar | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic
-
Halozyme TherapeuticsTerminatedCholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder AdenocarcinomaUnited States, Korea, Republic of, Thailand
-
Xuhua DuanRecruiting
-
University of UtahTerminated
-
First People's Hospital of HangzhouEnrolling by invitationMalignant Biliary Obstruction | Extrahepatic CholangiocarcinomaChina
-
National Cancer Center, KoreaBoston Scientific CorporationNot yet recruitingRadiotherapy | Biliary Tract Carcinoma | Radio-frequency Ablation
Clinical Trials on surgical treatment
-
HealthCore-NERIUniversity of California, San Diego; University of Maryland; University of Alabama... and other collaboratorsTerminated
-
Peking University Third HospitalRecruitingOsteoarthritis, Knee | Anterior Cruciate Ligament RuptureChina
-
Uppsala UniversityCompletedSpinal Fractures
-
Kolding SygehusOdense University Hospital; Karolinska University Hospital; Zealand University... and other collaboratorsRecruitingFracture Humerus of ShaftSweden, Finland, Denmark, Norway
-
Sahlgrenska University Hospital, SwedenActive, not recruitingRupture | Ultrasonography | Acute Disease | Athletic Injuries | Achilles Tendon RuptureSweden
-
Medtronic Neurovascular Clinical AffairsRecruiting
-
AO Innovation Translation CenterRecruitingLong Bone FracturesUnited States, Canada, Australia, Ghana, Chile, China, Germany, India, Pakistan, Venezuela, Spain, Croatia, Greece
-
AO Clinical Investigation and Publishing DocumentationActive, not recruitingFemoral Shaft FractureUnited States, Canada, Switzerland, Germany, Austria
-
Hospital Severo OchoaCompleted
-
University of CologneCompletedOutcome, Fatal | Vertebral Osteomyelitis | Spondylodiscitis